Interferon-mediated anti-angiogenic therapy for neuroblastoma

Cancer Letters

Volumn 228, Issue 1-2, 2005, Pages 163-170

  Streck, Christian J ^a,b   Ng, Catherine Y C ^a   Zhang, Youbin ^a   Zhou, Junfang ^a   Nathwani, Amit C ^c   Davidoff, Andrew M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Gene therapy; Interferon; Neuroblastoma

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BETA INTERFERON; FUMAGILLOL CHLOROACETYLCARBAMATE; NAKED DNA; PIGMENT EPITHELIUM DERIVED FACTOR; RETROVIRUS VECTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL THERAPY; CARCINOGENESIS; CYTOSTASIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; GENE THERAPY; HEMANGIOMA; HEMANGIOMATOSIS; HEMANGIOPERICYTOMA; HUMAN; IMMUNOMODULATION; LONG TERM CARE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SOLID TUMOR; TRANSGENE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

MURINAE;

EID: 23944441682     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.11.063     Document Type: Review

References (44)

1. A. Isaacs, J. Lindenmann, and R.C. Valentine Virus interference. II. Some properties of interferon Proc. R. Soc. Lond. B. Biol. Sci. 147 1957 268 273
2. J. Folkman Clinical applications of research on angiogenesis N. Engl. J. Med. 333 1995 1757 1763
3. J. Folkman The role of angiogenesis in tumor growth Semin. Cancer Biol. 3 1992 65 71
4. J.M. Pluda Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies Semin. Oncol. 24 1997 203 218
5. J. Folkman What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82 1990 4 6
6. L.A. Liotta, P.S. Steeg, and W.G. Stetler-Stevenson Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation Cell 64 1991 327 336
7. I.J. Fidler, and L.M. Ellis The implications of angiogenesis for the biology and therapy of cancer metastasis Cell 79 1994 185 188
8. J. Folkman, and D. Ingber Inhibition of angiogenesis Semin. Cancer Biol. 3 1992 89 96
9. R. Bicknell, and A.L. Harris Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis Semin. Cancer Biol. 3 1992 399 407
10. D. Ribatti, G. Alessandri, A. Vacca, M. Iurlaro, and M. Ponzoni Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo Int. J. Cancer 77 1998 449 454
11. T. Fotsis, S. Breit, W. Lutz, J. Rossler, E. Hatzi, and M. Schwab Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells Eur. J. Biochem. 263 1999 757 764
12. A. Eggert, M.A. Grotzer, N. Ikegaki, X.G. Liu, A.E. Evans, and G.M. Brodeur Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells Cancer Res. 62 2002 1802 1808
13. D. Meitar, S.E. Crawford, A.W. Rademaker, and S.L. Cohn Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma J. Clin. Oncol. 14 1996 405 414
14. A. Eggert, N. Ikegaki, J. Kwiatkowski, H. Zhao, G.M. Brodeur, and B.P. Himelstein High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas Clin. Cancer Res. 6 2000 1900 1908
15. E. Nagabuchi, W.E. VanderKolk, Y. Une, and M.M. Ziegler TNP-470 antiangiogenic therapy for advanced murine neuroblastoma J. Pediatr. Surg. 32 1997 287 293
16. E. Wassberg, S. Pahlman, J.E. Westlin, and R. Christofferson The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats Pediatr. Res. 41 1997 327 333
17. S. Shusterman, S.A. Grupp, R. Barr, D. Carpentieri, H. Zhao, and J.M. Maris The Angiogenesis Inhibitor TNP-470 Effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease Clin. Cancer Res. 7 2001 977 984
18. E.S. Kim, A. Serur, J. Huang, C.A. Manley, K.W. McCrudden, and J.S. Frischer Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma Proc. Natl Acad. Sci. USA 99 2002 11399 11404
19. A.M. Davidoff, M.A. Leary, C.Y. Ng, and E.F. Vanin Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo J. Pediatr. Surg. 36 2001 30 36
20. A.M. Davidoff, M.A. Leary, C.Y. Ng, and E.F. Vanin Retroviral vector-producer cell mediated angiogenesis inhibition restricts neuroblastoma growth in vivo Med. Pediatr. Oncol. 35 2000 638 640
21. S.E. Crawford, V. Stellmach, M. Ranalli, X. Huang, L. Huang, and O. Volpert Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity J. Cell Sci. 114 2001 4421 4428
22. C.J. Streck, Y. Zhang, J. Zhou, C. Ng, A.C. Nathwani, and A. Davidoff Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth J. Pediatr. Surg. 136 2004 183 189
23. T. Browder, C.E. Butterfield, B.M. Kraling, B. Shi, B. Marshall, M.S. O'Reilly, and J. Folkman Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res. 60 2000 1878 1886
24. E.S. Kim, S.Z. Soffer, J. Huang, K.W. McCrudden, A. Yokoi, and C.A. Manley Distinct response of experimental neuroblastoma to combination antiangiogenic strategies J. Pediatr. Surg. 37 2002 518 522
25. G. Klement, S. Baruchel, J. Rak, S. Man, K. Clark, and D.J. Hicklin Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J. Clin. Invest. 105 2000 R15 R24
26. T. Udagawa, A. Fernandez, E.G. Achilles, J. Folkman, and R.J. D'Amato Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy Fed. Am. Soc. Exp. Biol. J. 16 2002 1361 1370
27. A.L. Feldman, and S.K. Libutti Progress in antiangiogenic gene therapy of cancer Cancer 89 2000 1181 1194
28. M.G. Kaplitt, P. Leone, R.J. Samulski, X. Xiao, D.W. Pfaff, K.L. O'Malley, and M.J. During Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain Nat. Genet. 8 1994 148 154
29. R.W. Herzog, J.N. Hagstrom, S.H. Kung, S.J. Tai, J.M. Wilson, and K.J. Fisher Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus Proc. Natl Acad. Sci. USA 94 1997 5804 5809
30. H. Nakai, S.R. Yant, T.A. Storm, S. Fuess, L. Meuse, and M.A. Kay Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo J. Virol. 75 2001 6969 6976
31. P.W. Hargrove, E.F. Vanin, G.J. Kurtzman, and A.W. Nienhuis High-level globin gene expression mediated by a recombinant adeno-associated virus genome that contains the 3′ gamma globin gene regulatory element and integrates as tandem copies in erythroid cells Blood 89 1997 2167 2175
32. T. Tanabe, S.L. Kominsky, P.S. Subramaniam, H.M. Johnson, and B.A. Torres Inhibition of the glioblastoma cell cycle by type I IFNs occurs at both the G1 and S phases and correlates with the upregulation of p21(WAF1/CIP1) J. Neurooncol. 48 2000 225 232
33. J.M. Kirkwood, T. Richards, H.M. Zarour, J. Sosman, M. Ernstoff, and T.L. Whiteside Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690 Cancer 95 2002 1101 1112
34. Q. Chen, B. Gong, A.S. Mahmoud-Ahmed, A. Zhou, E.D. Hsi, and M. Hussein Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma Blood 98 2001 2183 2192
35. H.F. Dvorak, and I. Gresser Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice J. Natl Cancer Inst. 81 1989 497 502
36. J.W. Slaton, P. Perrotte, K. Inoue, C.P. Dinney, and I.J. Fidler Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule Clin. Cancer Res. 5 1999 2726 2734
37. Z. von Marschall, A. Scholz, T. Cramer, G. Schafer, M. Schirner, and K. Oberg Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis J. Natl Cancer Inst. 95 2003 437 448
38. J.W. Slaton, T. Karashima, P. Perrotte, K. Inoue, S.J. Kim, and J. Izawa Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder Clin. Cancer Res. 7 2001 2840 2853
39. R.A. Ezekowitz, J.B. Mulliken, and J. Folkman Interferon alfa-2a therapy for life-threatening hemangiomas of infancy N. Engl. J. Med. 326 1992 1456 1463
40. F. Belardelli, M. Ferrantini, E. Proietti, and J.M. Kirkwood Interferon-alpha in tumor immunity and immunotherapy Cytokine Growth Factor Rev. 13 2002 119 134
41. J.M. Kirkwood, J.G. Ibrahim, V.K. Sondak, J. Richards, L.E. Flaherty, and M.S. Ernstoff High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J. Clin. Oncol. 18 2000 2444 2458
42. C. Buzio, S. Andrulli, R. Santi, L. Pavone, R. Passalacqua, and D. Potenzoni Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma Cancer 92 2001 2286 2296
43. S. Einhorn, and D. Grander Why do so many cancer patients fail to respond to interferon therapy? J. Interferon Cytokine Res. 16 1996 275 281
44. P. Salmon, J.Y. Le Cotonnec, A. Galazka, A. Abdul-Ahad, and A. Darragh Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers J. Interferon Cytokine Res. 16 1996 759 764